Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.

Targeted oncology - 1 Jun 2017

Garlan Fanny, Blanchet Benoit, Kramkimel Nora, Puszkiel Alicja, Golmard Jean-Louis, Noe Gaelle, Dupin Nicolas, Laurent-Puig Pierre, Vidal Michel, Taly Valerie, Thomas-Schoemann Audrey

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) has been reported as a prognostic marker in melanoma. In BRAF V600-mutant melanoma, a plasma under-exposure to vemurafenib could favor emerging resistance but no biological data are available to support this hypothesis. OBJECTIVE: We aimed to investigate the relationship between vemurafenib plasma concentrations and the ctDNA plasma concentration during follow-up of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Melanoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Survival Analysis

Share to Vemurafenib

Source

Identifiers

PMID: 28527094
DOI: 10.1007/s11523-017-0491-8

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.PMID 28527094Read ↗

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Semantic proximity Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)Semantic proximity Read ↗

Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.Semantic proximity Read ↗

Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.Semantic proximity Read ↗

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.Semantic proximity Read ↗

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsSemantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNASemantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.